Anti-Mouse CD152 (CTLA-4) [Clone 9H10] — Purified in vivo PLATINUM™ Functional Grade

Clone 9H10 is a Syrian hamster monoclonal antibody against mouse CTLA-4 (CD152) that is widely used in in vivo mouse studies, particularly in cancer immunotherapy models to block CTLA-4-mediated inhibition of T cell responses.

In in vivo mouse studies, clone 9H10 is utilized primarily for:

• Blocking CTLA-4: 9H10 prevents CTLA-4 from binding to its ligands (CD80/CD86), thereby enhancing T cell activation by allowing co-stimulation via CD28.
• Depleting regulatory T cells (Tregs): 9H10 has been shown to selectively deplete intra-tumoral Tregs, which contributes to reversing local immune suppression in tumor models; in some studies, it demonstrated slightly stronger Treg depletion than other anti-CTLA-4 clones.
• Cancer immunotherapy research: 9H10 was one of the first antibodies to demonstrate that CTLA-4 blockade can enhance anti-tumor immune responses in vivo, as shown in seminal experiments with murine models (e.g., Leach et al., 1996).
• Mechanistic studies: Researchers use 9H10 to study the effects of CTLA-4 inhibition on T cell activation, proliferation, tumor infiltration, and modulation of the tumor microenvironment.

Additional technical details:

• Isotype: Syrian hamster IgG.
• Applications: Validated for in vivo functional studies, as well as for detection by Western blot, immunohistochemistry, flow cytometry, and ELISA.

9H10, along with other anti-CTLA-4 clones (like 9D9 and UC10-4F10-11), is available in endotoxin-free, pathogen-tested preparations suitable for preclinical therapeutic studies in mice.

The correct storage temperature for sterile packaged clone 9H10 (anti-CTLA4 antibody) depends on the required storage duration:

• For short-term storage (up to 1 month): 2–8?°C (refrigerator).
• For long-term storage: ??–70?°C (ultra-low freezer), after aseptically aliquoting without diluting.

Some suppliers recommend –20?°C for certain related monoclonal antibody clones, but the most authoritative sources for sterile, functional-grade 9H10 specify 2–8?°C for short-term and ?–70?°C for long-term storage.

To preserve sterility and antibody activity:

• Avoid repeated freeze/thaw cycles.
• Consult the lot-specific datasheet from your manufacturer.
• Store in original packaging until use whenever possible.

If you require storage for longer than one month, aliquot into working volumes and store at ?–70?°C. For general laboratory use, short-term storage at 2–8?°C is acceptable and matches common antibody handling practice.

Commonly, the antibody 9H10 is used in research targeting mouse CTLA-4 (CD152), particularly in cancer immunology, to block the interaction between CTLA-4 and its ligands. In this context, several other antibodies and proteins are routinely used alongside 9H10 for both mechanistic studies and control purposes:

• Other anti-CTLA-4 antibodies: Notably, 9D9 and UC10-4F10-11 are two frequently used clones for mouse CTLA-4 studies, similar to 9H10. They differ in their isotypes, depletion efficacy of regulatory T cells (Tregs), and nuanced functional properties in neutralization and depletion assays.
• Anti-CD28 antibody: As CD28 is the major costimulatory receptor that competes with CTLA-4 for binding to B7 ligands, anti-CD28 antibodies are often included to study T cell activation pathways and costimulatory blockade mechanisms in parallel with CTLA-4 targeting.
• Anti-PD-1 and anti-PD-L1 antibodies: In immune checkpoint studies, particularly in tumor models, anti-PD-1 and anti-PD-L1 are widely co-administered to examine combination checkpoint inhibition effects, often in synergy with CTLA-4 blockade using 9H10.
• Markers for T cells and regulatory T cells (Tregs): Antibodies such as anti-CD3, anti-CD4, anti-CD8 (for T cell identification), and anti-Foxp3 (for Tregs) are used in flow cytometry and immunohistochemistry to analyze immune populations altered by 9H10 treatment.
• Isotype control antibodies: Appropriate hamster IgG isotype controls are routinely used alongside 9H10 to account for non-specific Fc-mediated effects.

Additionally, other immune stimulatory/coinhibitory markers such as ICOS may be probed, and when 9H10 is used in mechanistic signaling studies, staining for cytokines, activation markers, or proliferation indicators (e.g., anti-Ki67) is common.

When 9H10 is described as an anti-influenza hemagglutinin stalk antibody (in a separate context; see ), it is often compared and used with other broadly neutralizing antibodies such as CR8020 and CR8043 for epitope mapping and functional comparison in influenza research. In that literature, these antibodies are assessed together to map cross-reactivity and escape mutations, providing a set of complementary reagents.

In summary, when 9H10 is used for mouse CTLA-4 blockade, it is most often utilized with:

• Other anti-CTLA-4 clones (9D9, UC10-4F10-11)
• Anti-CD28, anti-PD-1/PD-L1 antibodies
• T cell and Treg markers (anti-CD3, anti-CD4, anti-CD8, anti-Foxp3)
• Isotype controls
  When used in the context of influenza research as an anti-HA stalk antibody, it is used with structurally and functionally similar bnAbs, such as CR8020 and CR8043, for comparative and mapping studies.

The scientific literature consistently identifies clone 9H10 as a key anti–CTLA-4 monoclonal antibody with distinctive efficacy and biological effects, especially in mouse models of cancer immunotherapy.

Key findings from prominent citations:

• Intra-tumoral Regulatory T cell (Treg) depletion: Clone 9H10 is notable for its ability to selectively deplete intratumoral Tregs—a subpopulation of cells in the tumor microenvironment that suppress immune responses—without affecting Tregs in the spleen or lymph nodes. This action is not matched by all other anti-CTLA-4 clones (e.g., 9D9), as they lack the Fc region required for antibody-dependent cellular cytotoxicity (ADCC)-mediated depletion.

• Potency in anti-tumor memory response: Mice treated with 9H10 displayed superior memory immune responses; after tumor re-challenge, these mice showed minimal tumor regrowth, indicating long-lasting anti-tumor immunity. This effect was notably stronger with 9H10 than with other anti-CTLA-4 clones (such as 9D9 or UC10-4F10-11) or with anti–PD-1 antibodies.

• Mechanism—Blockade and T cell co-stimulation: 9H10 blocks CTLA-4 from binding its ligands (CD80/CD86), thereby enhancing T cell activation and co-stimulation. This blockade directly promotes immune effector responses and is responsible for its neutralizing effect both in vitro and in vivo.

• Comparative efficacy in tumor models: In preclinical mouse cancer models, 9H10 treatment has been linked to longer survival and better tumor control compared to control or other clones. In melanoma models, its intratumoral Treg depletion was marginally stronger than 9D9, indicating clone-specific pharmacodynamics.

• Requirement for Fc domain: The anti-tumor effects of anti-CTLA-4 therapy, including 9H10, are dependent on an intact Fc domain, underscoring the importance of ADCC activity for intratumoral Treg depletion and therapeutic efficacy in vivo.

Additional points:

• 9H10 is a Syrian hamster IgG; this is distinct from other commonly used clones (such as 9D9, a mouse IgG, and UC10-4F10-11, an Armenian hamster IgG), which can influence their in vivo activity, tissue distribution, and detection capabilities.

• 9H10 is also widely used for functional studies and for detecting murine CTLA-4 in assays like Western blot; however, UC10-4F10-11 is preferred for flow cytometry.

In summary, clone 9H10 is characterized in scientific literature as a potent, functionally distinct anti–CTLA-4 antibody widely used for preclinical immuno-oncology research due to its strong Treg-depleting capability within tumors, robust anti-tumor memory induction, and requirement for an Fc-mediated mechanism.